Assessing the Galleri Test: A Promising Yet Unproven Cancer Screening Tool

Cancer continues to evoke fear among many, despite heart disease having a higher death toll. Its impact is profound, affecting numerous individuals and their families, and often requiring harsh treatments. With elevated cancer rates among younger populations, this disease results in a significant loss of potential life years.

A new blood test called the Galleri test, developed by biotech company GRAIL, claims to screen for more than 50 types of cancer simultaneously before any symptoms arise. However, a deeper inspection reveals that it may not deliver the hoped-for universal screening solution.

Understanding the Galleri Test

The Galleri test is part of a new generation of multi-cancer early detection tests. While it does not diagnose cancer definitively, a positive result indicates the need for further testing to confirm the presence and type of cancer. It aims to function as a screening test akin to mammography for breast cancer or PSA testing for prostate cancer, but promises the added benefit of detecting a wider range of cancers.

This test identifies DNA fragments in the bloodstream that are linked to cancer. Tumor cells produce unique DNA markers, known as methylation patterns, which the Galleri test analyzes using advanced machine learning techniques.

Strengths of the Galleri Test

The Galleri test's advantage lies in its capability to detect signals from over 50 cancers, including 12 types that account for a significant portion of U.S. cancer-related deaths, such as lung and pancreatic cancers. Notably, it can also indicate where in the body the potential tumor may have originated. Current screening methods primarily focus on just four cancer types.

With this test, only about 0.5% of individuals are incorrectly informed they have cancer (a false positive), which is significantly lower than many existing screening tests, where rates can extend to 10%. This low rate of false positives means that a positive Galleri result is more likely than not to indicate an actual cancer diagnosis, with approximately 52% of positive results confirming the presence of cancer.

Limitations to Consider

Despite its promising features, the Galleri test does have notable drawbacks. It struggles with early-stage cancer detection, which is the primary goal of any cancer screening tool. In clinical trials, it correctly identified cancer only 31% of the time across all stages, missing nearly 69% of cases. Of the cancers detected, only about 60% were at an early stage, comparable to outcomes from traditional screening methods.

One significant concern is that the Galleri test has yet to demonstrate its capability to lower cancer mortality or reduce the likelihood of advanced cancer diagnoses. Although preliminary data hinted at a potential decrease in late-stage cancer rates, the findings require further investigation before any definitive conclusions can be drawn.

FDA Advisory Panel Insights

On September 23, 2026, an FDA advisory panel recommended the Galleri test for approval, although this recommendation does not imply full FDA endorsement. The panel suggested removing the term